Is severe liver disease a common outcome for people with chronic hepatitis C?

被引:67
作者
Dore, GJ [1 ]
Freeman, AJ [1 ]
Law, M [1 ]
Kaldor, JM [1 ]
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia
关键词
cirrhosis; clinical outcome; community-based cohorts; disease progression; hepatitis C; Markov modeling; natural history;
D O I
10.1046/j.1440-1746.2002.02730.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
For people with chronic hepatitis C, an assessment of their risk of progression to advanced liver disease is a major priority. Early studies of the natural history of chronic hepatitis C suggested that development of cirrhosis was a relatively common outcome, even in the first 20 years of infection. These studies were either cross-sectional liver clinic series of people referred for assessment to specialist clinics, or longitudinal cohorts of people with post-transfusion hepatitis. More recent studies (particularly longitudinal community-based cohorts) indicate that liver disease progression is generally slow, and that a minority of people with chronic hepatitis C will develop advanced liver disease. Based on an extensive review of studies reporting on chronic hepatitis C natural history, we have developed a Markov model of liver disease progression. This model estimates that the risk of progression to cirrhosis is 7% and 20% after 20 and 40 years of infection, respectively. Corresponding estimates for hepatitis C-related mortality are 1% and 4%. However, liver disease progression is highly variable, and certain subgroups of people with chronic hepatitis C are at increased risk of advanced liver disease. Those groups include people with a heavy alcohol intake, those who have coinfection with HIV or HBV, and those who have already progressed to moderate to severe hepatic fibrosis. (C) 2002 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:423 / 430
页数:8
相关论文
共 62 条
[1]  
ALBERTI A, 1997, HEPATOLOGY S, V22, P38
[2]  
BARRERA JM, 1995, HEPATOLOGY, V21, P639, DOI 10.1002/hep.1840210306
[3]   Clinical course and risk factors of hepatitis C virus related liver disease in the general population:: report from the Dionysos study [J].
Bellentani, S ;
Pozzato, G ;
Saccoccio, G ;
Crovatto, M ;
Crocè, LS ;
Mazzoran, L ;
Masutti, F ;
Cristianini, G ;
Tiribelli, C .
GUT, 1999, 44 (06) :874-880
[4]   Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C [J].
Bennett, WG ;
Inoue, Y ;
Beck, JR ;
Wong, JB ;
Pauker, SG ;
Davis, GL .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) :855-+
[5]  
BENVEGNU L, 1994, CANCER, V74, P2442, DOI 10.1002/1097-0142(19941101)74:9<2442::AID-CNCR2820740909>3.0.CO
[6]  
2-#
[7]   Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis [J].
Benvegnu, LB ;
Pontisso, P ;
Cavalletto, D ;
Noventa, F ;
Chemello, L ;
Alberti, A .
HEPATOLOGY, 1997, 25 (01) :211-215
[8]   Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy [J].
Bonkovsky, HL ;
Woolley, JM .
HEPATOLOGY, 1999, 29 (01) :264-270
[9]   Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study [J].
Bruno, S ;
Silini, E ;
Crosignani, A ;
Borzio, F ;
Leandro, G ;
Bono, F ;
Asti, M ;
Rossi, S ;
Larghi, A ;
Cerino, A ;
Podda, M ;
Mondelli, MU .
HEPATOLOGY, 1997, 25 (03) :754-758
[10]  
Chiba T, 1996, AM J GASTROENTEROL, V91, P1195